Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions Monday July 8

MoPeB3275 Use of antiretroviral therapy among HIVseropositive patients attended in a public
hospital in Peru.
M Vidal', E Gotuzzo', ] Echevarria', C Seas',
K Verdonck2, FSamalvides' (Peru; 2Belgium)
MoPeB3276 A successful pilot treatment program using
recovered medications
BA Boyle', S C Ball/', ] Adenekan2, Y Ogun,
J Lytton', Jacobs' (United States; 2Nigeria)
MoPeB3277 Access to anti retrovirals (ARV) in Mexico 1998 -2001
P Uribe-Zdhfiga, C Magis-Rodrfguez, G HerndndezTepichin, P Rivera-Reyes, A Stanford-Camargo
(Mexico)
MoPeB3278 The patient makes the decision! Strategies to
improve drug delivery and patient adherence of
ARV therapy in a resource limited setting
VA Prabhu S Shyamprasad, J Williams (India)
MoPeB3279 30-months follow-up of a pilot study of HAART in
Senegal
C Laurent', N F Ngom Gueye2, R Schiemann',
N Diakhat'2, M Gueye2, A Canestri', PS Sow2,
MA Faye2, N C Tourd Kane2, F Lidgeois',
L Vergne', R Landman', S Mboup2, I Ndoye2,
E Delaporte' (France; 2Senegal)
MoPeB328o Role of viral infections HCV and HBV in liver toxicity
among patients receiving antiretroviral treatment in
HIV drugs access initiative in Cote d'lvoire
C Dakour, S Eholie, R Aka-Kakou, E Bissagnene,
R Konan-Koko, A Kadio (Cote d'lvoire)
MoPeB3281 Counseling for antiretroviral therapy: program
development and implementation - Botswana
Experience
K More (Botswana)
MoPeB3282 Dental reflections: Oral management in HIV
infection - the mouth mirror signals changes in
HIV disease progression
S Fletcher, C Tsoukas (Canada)
MoPeB3283 Utility of a "Grading Table" for assessing HAART
adherence
KH Wong, CFHo, O W Fong, G C Y Yuen, SSLee
(China)
MoPeB3284 Adherence support: the importance of linkages
to clinical care
L ] W Weiss, P T F French, MD W Waters,
B D A Agins, R S F Finkelstein (United States)
MoPeB3285 Tailored adherence interventions for HIV-infected
adults based on the Transtheoretical Model of
Change
Dj Konkle-Parker (United States)
MoPeB3286 A randomized controlled trial of a multidimensional
intervention to enhance adherence to antiretroviral
therapy in HIV-infected patients with a history of
alcohol problems
JH Samet, N] Horton, K Dukes, S Meli, T Tripp,
C LaBelle, K A Freedberg (United States)
MoPeB3287 Patients prefer once-daily dosing of antiretroviral
medication
F Papatheofanis, Mukherjee, V Tuomari,
S Jackson (United States)
MoPeB3288 Issues of interest of HIV patients in therapy
compliance groups
AS Amorim D L Estevam, WK Alencar,
MM G Gongalves, C P Nocentini, A Oliveira (Brazil)
MoPeB3289 Tolerance and activity of an unusual triple
nucleoside therapy with AZT, 3TC, and ddl in
naive patients from French Guiana

F Bissuel, P Couppie, M El Guedj, S Mason,
R Pradinaud (French Guiana)

MoPeB329o HIV patients prefer once-daily regimens
D Bass, M F Smith (United States)
MoPeB3291 Evaluation of a pharmaceutical care program to
improve the adherence to antiretroviral therapy
C Codina, M Tuset, 0 Delgado, B Garcfa,
O Morancho, A Escobar, B Martinez, PAmador,
E Estadn, A Sainz, N Martinez, S Cal, M R Gdmez,
O lbarra, A Carmona, I Jimdnez, C Moriel, ] Ledn,
L Caro, I Castillo, P Bachiller, B Irastorza, M Gine,
M Sala, R Santolaya, A Lluch, A Iruin, JAlfaro (Spain)
MoPeB3292 Compliance to antiretroviral therapy in
Cameroon: against all odds
L Ciaff i, G B W Tengpe', I Titao', M Ngalle',
A Ndoumbe', A Bourgeois2, C Laurent, E Mpoudi
Ngole', I Andrieux-Meyer3 (Cameroon; 2France;
3Switzerland)
MoPeB3293 Once daily HAART: a new paradigm for HIV
treatment success
P D Chambliss F G Reyes, D Rusu, H A Grossman
(United States)
MoPeB3294 Supporting adherence to antiretroviral therapy:
the "S.O.S. therapy" project
G C Orofino, S Carosella, P Leombruni,
M Bolgiani, R Balducci, M Barbaro, A Romano,
A Sorbo (Italy)
MoPeB3295 Psychosocial influences of attitudes and beliefs
toward medication adherence in HIV+ persons
na've to antiretroviral therapy: a cross-sectional
survey
N R Reynolds', MA Testa', L G Marc',
MA Chesney, J L Neidig', S R Smith', S Vella2,
G G Robbins' (United States; 2Italy)
MoPeB3296 Antiretroviral therapy adherence. Impact of the
psychological support
E Melds, J del Pozo, V Ibarra, J R Blanco, ] A Oteo
(Spain)
MoPeB3297 HIV Therapy, Self-defined Symptoms and Quality
of Life for HIV positive patients in Japan
M Watanabe E Nakano, S Ito, M Ogane, K Ikeda,
S Oka (apan)
MoPeB3298 Virologic outcomes associated with a
presonalized medication adherence program
J Gilmore R Maniglia, A Norris, M Duffalo,
K Wolff, J R Kostman (United States)
MoPeB3299 Prevalence of childhood sexual abuse among
HIV-infected patients in an inner city clinic
S Mannheimer, J Franks, N Holson, M Perkins,
A Rita, H Dohnert, E Wilson, S Findley
(United States)
MoPeB33oo Effect of an adherence program on HIV viral load
in treatment experienced patients with a history
of substance abuse and/or mental health illness
A Battaglioli-DeNero A Gallucci, D Fish,
K Stellrecht, P Piliero, G Clifford (United States)
MoPeB33ol Intensive adherence interventions improve
virologic repsonse to antiretroviral therapy in
treatment naive patients
LD Esch, K I Klem, H Hardy, H E Wynn,
M ]Shelton, R G Hewitt, G D Morse
(United States)
MoPeB33o2 Treatment Results in "real life"- better than in
clinical trials?
M Halvarsson, M Christiansen, S Lindbdck,
A Sonnerborg, P 0 Pehrson (Sweden)
MoPeB33o3 Bottom up, top down: reducing degrees of
separation between disadvantaged HIV in/affected
women and care providers through needs

assessments and functional level evaluations
A Boyer K ] London, D Indyk (United States)
XIV International AIDS Conference BARCELONA - JULY 7-12

Monday

41